-+ 0.00%
-+ 0.00%
-+ 0.00%

Generate Biomedicines partners with Zealand Pharma to develop AI-designed protein therapeutics for metabolic diseases

PUBT·10/13/2026 20:31:06
Listen to the news
Generate Biomedicines partners with Zealand Pharma to develop AI-designed protein therapeutics for metabolic diseases
  • Generate Biomedicines entered a multi-target collaboration with Zealand Pharma to develop AI-engineered multispecific protein therapeutics for obesity.
  • Agreement targets obesity and other metabolic diseases, combining Zealand’s metabolic expertise with Generate’s generative AI and experimental validation platform.
  • Deal includes USD 30 million upfront, up to USD 35 million in early preclinical milestones, up to nearly USD 1.2 billion in total milestones.
  • Generate also receives tiered royalties on two initial programs, with an option to add a third program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610131630PRIMZONEFULLFEED9844857) on October 13, 2026, and is solely responsible for the information contained therein.